Alnylam Pharmaceuticals net common equity issued/repurchased for the twelve months ending March 31, 2025 was $0.778B, a 103.75% increase year-over-year.
Alnylam Pharmaceuticals annual net common equity issued/repurchased for 2024 was $0.303B, a 105.44% increase from 2023.
Alnylam Pharmaceuticals annual net common equity issued/repurchased for 2023 was $0.147B, a 43.14% decline from 2022.
Alnylam Pharmaceuticals annual net common equity issued/repurchased for 2022 was $0.259B, a 5.32% increase from 2021.
Alnylam Pharmaceuticals Net Common Equity Issued/Repurchased 2010-2025 | ALNY